{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097535","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.159527+00:00","generated_at":"2026-05-15T18:04:43.981776+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Boundless Bio Q4 net loss $12.9M; cash $107.6M; ceases POTENTIATE enrollment; BBI-940 trial enrolling","bullets":["Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.","Cash, cash equivalents, and short-term investments total $107.6M; expected runway into H2 2028 through initial proof-of-concept readout for KOMODO-1.","Ceased enrollment in Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) due to market considerations and prioritization of BBI-940 program.","KOMODO-1 first-in-human trial of BBI-940 (oral Kinesin degrader) open for enrollment in ER+/HER2- and TNBC-LAR breast cancer.","Director Christine Brennan resigned effective March 3, 2026 due to new role at Johnson & Johnson Development Corp., no disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097535","json":"https://secwatch.observer/filing/0001193125-26-097535.json","markdown":"https://secwatch.observer/filing/0001193125-26-097535.md","text":"https://secwatch.observer/filing/0001193125-26-097535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/0001193125-26-097535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/bold-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:04:43.981776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}